More positive data for the leading PARP blocker, Lynparza (olaparib), are being presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
Developed by AstraZeneca (LSE: AZN) in partnership with Merck & Co (NYSE: MRK), the cancer med is being developed as an option for people with prostate cancer in the Phase III PROpel trial.
In the trial, a combination of Lynparza and hormone therapy produced a statistically-significant and clinically-meaningful improvement in radiographic progression-free survival versus current standard-of-care.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze